MedPath

Pre-operative Antihypertension Strategies-Carotid Artery Stenting

Phase 3
Not yet recruiting
Conditions
Carotid Stenosis
Interventions
Drug: administering RASI (the trade name or universal name will not be stipulated) before stenting
Drug: administering CCB (the trade name or universal name will not be stipulated) before stenting
Registration Number
NCT05905848
Lead Sponsor
West China Hospital
Brief Summary

Carotid artery stenting (CAS) is one of major treatments in prevention of ischemic stroke. Because of sinus reflex due to stenting and balloon dilatation, persistent post-surgery hypotension is a common perioperative event. Persistent hypotension can lead to perioperative adverse events like ischemic stroke, myocardial infraction, renal failure and death; or more usually, it prolongs length of stay and hospital expenses. Renin-angiotensin-aldosterone inhibitor (RASI) could inhibit the release of catecholamine and may lead to higher rate of persistent hypotension after CAS compared to other hypertensives.Thus, the investigators aim to investigate the effect of pre-operation antihypertensive drugs on persistent hypotension after stenting, and followed burden in carotid artery stenting comorbid with hypertension patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
560
Inclusion Criteria
  • age ≥ 18
  • have a history of TIA or nondisabling ischemic stroke within the past 6 months (symptomatic) with ipsilateral initial part of EICA stenosis ≥ 50 % or asymptomatic with initial part of EICA stenosis ≥ 70%, and the cause of stenosis was atherosclerosis
  • have hypertension requiring hypertensives
  • modified Rankin scale (mRS) before stenting < 3
Exclusion Criteria
  • with ipsilateral tandem stenosis
  • with history of operation in contralateral carotid artery, like stenting, endarterectomy and bypass.
  • requiring operation in contralateral carotid artery in the same admission.
  • requiring general anesthesia in the same operation (stenting)
  • with contraindication to carotid stenting, such as Inability to tolerate surgery due to organ dysfunction, cerebral aneurism, cerebral hemorrhage in 3 months, myocardial infraction or large-area cerebral infraction within 2 weeks, extreme tortuosity of the vessel
  • allergic to Calcium channel blockers, angiotensin receptor blockers or hydrochlorothiazide
  • pregnancy
  • with concomitant medication as following: Azole antifungals, macrolides antibiotics, cardiac calcium channel blockers, Rifampicin, sildenafil, simvastatin, immunosuppressants, antidepressants, valproic acid, cimetidine, aliskiren, NSAIDs, protease inhibitors (ritonavir) and drugs that affect potassium in the blood
  • with hepatic insufficiency, renal insufficiency, kidney transplantation, diabetic nephropathy, biliary obstructive disease, or the presence of end-stage disease affecting clinical prognosis assessment (such as end-stage cancer, end-stage heart disease, liver failure, renal failure, pulmonary failure)
  • with depression, schizophrenia, bipolar disorder, epilepsy, tuberculosis, AIDS, primary hyperaldosteronism, hyperkalemia, hypercalcemia, hyperuricemia, gout
  • participating other trails which would affect the evaluation of outcomes
  • with reserpine and clonidine intake within 1 week

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
RASI groupadministering RASI (the trade name or universal name will not be stipulated) before stentingAdminister RASI, with or without other antihypertensives except for CCB, and blood pressure should be controlled within the target range (140/90 mmHg). RASI intaking starts at least 5 days before stenting.
CCB groupadministering CCB (the trade name or universal name will not be stipulated) before stentingAdminister CCB, with or without other antihypertensives except for RASI, and blood pressure should be controlled within the target range (140/90 mmHg). CCB intaking starts at least 5 days before stenting.
Primary Outcome Measures
NameTimeMethod
The incidence of persistent post-surgery hypotensionthe first 24 hours after CAS

systolic blood pressure (SBP) \< 90 mmHg or requiring vasopressor with lasting \> 6 hours, and without evidence hypovolemia and heart failure

Secondary Outcome Measures
NameTimeMethod
Length of stay after surgeryFrom surgery to dicharge, up to 3 month.
Hospital expenses after surgery, based on payment list in hospital information systemFrom surgery to dicharge, up to 3 month.

Payment list in hospital information system for all patients will be recorded with permission and the hospital expenses after surgery will be caculated based on those records.

Difference of serum catecholamine (adrenalin, norepinephrine and dopamine) before and after surgery (all in unit of nmol/L)at morning (7 o'clock am) of the day of surgery and the first day after surgery
Difference of heart rate variability (HRV) before and after surgery24 hours before surgery to at least 24 hours after surgery
The incidence of bradycardia after surgerythe first 24 hours after CAS
The total incidence of stroke, myocardial infraction, renal failure and embolism of retinal arteriesFrom surgery to dicharge, up to 3 month.

Trial Locations

Locations (1)

West China Hospital, Sichuan University

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath